Alembic Pharmaceuticals has received U.S. Food and Drug Administration final approval for its abbreviated new drug application for Carbidopa, Levodopa and Entacapone Tablets in different strengths.

Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic ...

Feb 5 (Reuters) - Indian drugmaker Alembic Pharmaceuticals (ALEM.NS), opens new tab on Thursday reported lower third‑quarter profit on Thursday after taking a one-time charge linked to India's new ...

Alembic Pharmaceuticals Ltd on Monday said it has received tentative approval from the US health regulator for its Bosutinib tablets used in the treatment of certain types of cancer. The tentative ...

Alembic Pharmaceuticals was hit with a patent infringement lawsuit on Dec. 19 in New York Eastern District Court over its planned generic version of the glaucoma treatment LUMIGAN®. The action, ...

Alembic Pharmaceuticals was sued for patent infringement on Dec. 19 in New York Eastern District Court for seeking to market a generic version of glaucoma treatment Lumigan. The action, brought by ...

Accenture (NYSE: ACN) has invested, through Accenture Ventures, in Alembic, a leading AI-powered causal marketing intelligence platform that can determine which marketing campaigns deliver a return on ...

Causal artificial intelligence startup Alembic Technologies Inc. said today it has raised $145 million in a Series B growth round that increases its valuation almost 16-fold. It’s using a big chunk of ...

Alembic, a startup that offers AI-powered data analytics for marketers, said it has raised $145 million in a fundraising round that values the company at $645 million. Alembic’s software is designed ...

Alembic Technologies has raised $145 million in Series B and growth funding at a valuation 15 times higher than its previous round, betting that the next competitive advantage in artificial ...